Results 281 to 290 of about 126,024 (329)

Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy? [PDF]

Hepatobiliary Surg Nutr
Ono A, Hayes CN, Tsuge M, Oka S.
europepmc   +1 more source

Targeting MED8 enhances sorafenib sensitivity in hepatocellular carcinoma by disrupting epithelial-mesenchymal transition mechanisms. [PDF]

J Enzyme Inhib Med Chem
Li M, You X, Yuan T, He J, Xu Z, Liang S, Mao L, Jin A, Zhou X, Yi B, Li J, Tu Q.   +11 more
europepmc   +1 more source

Combining Transarterial Chemoembolization with Sorafenib Improves Survival in Selected Patients with Hepatocellular Carcinoma and Extrahepatic Spread: A Multicenter Real-World Study. [PDF]

J Hepatocell Carcinoma
Yuan Y, Qiao Y, Zhu Y, Guo P, Gou J, Liu K, Wang L, Zhao S, Zhang Y, Liu Y, Wang E, Liu L.   +11 more
europepmc   +1 more source

CD19‐CAR T‐cell therapy with sorafenib in post‐HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch—A case report and review of the literature

Aleksandra Oszer, Julia Kołodrubiec, Bartłomiej Pawlik, Paweł Marschollek, Natalia Ćwilichowska, Justyna Jakubowska, Karolina Bukowska-Straková, Marta Surman, Joanna Trelińska, Karolina Miarka‐Walczyk, Natalia Haze, K Liszka, Monika Mielcarek‐Siedziuk, Krzysztof Kałwak, Małgorzata Poręba, Agata Pastorczak, Szymon Janczar, Wojciech Młynarski   +17 more
openalex   +2 more sources

D-amino acid oxidase suppresses hepatocellular carcinoma via oxidizing D-amino acids. [PDF]

J Transl Med
Li Z, Fu C, Chen Y, Fang L, Liu W, Zhao J, Zhao J, Meng R, Pu R, Shi Y, Chen H, He Y, Jin Y, Ding Y, Cao G.   +14 more
europepmc   +1 more source

Design and synthesis of sorafenib-inspired benzofuran hybrids as VEGFR-2 inhibitors: antiproliferative evaluation, mechanistic insights, and docking studies in hepatocellular carcinoma. [PDF]

RSC Med Chem
Shehda MS, Almatary AM, Salem MSH, Aboutaleb MH, Takizawa S, Abdel Aziz YM, El-Sayed MAA, Elrayess R.   +7 more
europepmc   +1 more source

Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma.

JAMA Netw Open
Lau-Min KS, Tramontano AC, Iheanacho F, Abrams TA, Manz CR.   +4 more
europepmc   +1 more source

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Lancet, The, 2018
Matsatoshi Kudo, Kwang-Hyub Han, Fabio Piscaglia   +2 more
exaly   +2 more sources

Sorafenib in Advanced Hepatocellular Carcinoma

New England Journal of Medicine, 2008
, Vincenzo Mazzaferro, Jean-Frédéric Blanc   +2 more
exaly   +3 more sources

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Signal Transduction and Targeted Therapy, 2020
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately,
Weiwei Tang, Fan Wu, Qian Wang
exaly   +2 more sources